Log ind

“We’ll be a meaningful player, even in the lung market"

POLFOTO_4265997.jpg Top picks in English:

US-based pharma group Bristol-Myers Squibb has come under pressure in the field of immuno-oncology, but the company’s CFO believes they are still in a strong position, also in the all-important lung cancer niche. He is open to looking at external innovation in one particular area.

DNB sees huge potential in Norwegian biotech cluster

Norway-based financial services group DNB believes the Oslo Cancer Cluster has developed into one of Europe’s top biotech hubs. Norway’s life science industry is generally speaking more mature than a few years ago, says the group’s senior advisor for healthcare.

ANNONCE


ANNONCE